Advice
following a full submission
apixaban (Eliquis®) is accepted for use within NHS Scotland.
Indication under review: treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults.
One phase III study showed non-inferiority of apixaban versus standard anticoagulant therapy including a low molecular weight heparin in combination with a vitamin K antagonist for treatment of DVT/PE. In a 12 month phase III study apixaban demonstrated superiority versus placebo for the prevention of recurrent DVT/PE.
Download detailed advice181KB (PDF)
Medicine details
- Medicine name:
- apixaban (Eliquis)
- SMC ID:
- 1029/15
- Indication:
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults.
- Pharmaceutical company
- Pfizer/Bristol Myers Squbb
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 March 2015